Short-Term Survival in Breast Cancer: The Experience of the University of Malaya Medical Centre  by Ong, Teng Aik & Yip, Cheng Har
ASIAN JOURNAL OF SURGERY  VOL 26 • NO 3 • JULY 2003 169
070/2001
Original Article
Introduction
Breast cancer is a “lifelong” diagnosis that irreversibly changes
the lives of patients affected and their families.1 It is a disease
in which “cure” is often a relative term2 as recurrences can
appear many years after an apparent “cure”. While the study of
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long-term prognostic factors is of great interest, knowledge
about prognostic variables affecting short-term outcome is no
less important to clinicians and patients. The peak incidence
of recurrence is in the first 2 to 5 years after diagnosis.3 This is
a demanding period as decisions on adjuvant therapies are
made and complications of the disease and its treatment are
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OBJECTIVE: To study the impact of various clinicopathological factors on short-term survival in a cohort of
breast cancer patients treated at the University of Malaya Medical Centre (UMMC).
METHODS: All cases of breast cancer treated at UMMC from January 1999 to June 2001, except for stage IV
disease, were included in the study. Survival analysis was carried out using Kaplan-Meier for univariate analysis
and Cox regression for multivariate analysis. The log-rank test was used to test the significance of differences
between the different survival curves.
RESULTS: A total of 385 patients were included. The mean patient age at presentation was 50.3 years (SD,
11.4); 198 (51.4%) patients had lymph node-positive disease, and 187 (48.6%) had node-negative disease. The mean
follow-up period was 18.7 months (SD, 8.8). The Malay ethnic group, tumours of larger size, node-positive disease,
more than five positive lymph nodes, oestrogen receptor (ER) negativity and the presence of lymphovascular
invasion were significant prognostic factors for shorter recurrence-free survival (RFS) in the univariate analysis.
In the multivariate analysis, ER negativity was the only independent adverse prognostic factor for RFS. For overall
survival (OS), tumours of larger size, node-positive disease, more than five positive lymph nodes, ER negativity and
high grade tumours were associated with significantly shorter OS. However, more than five positive lymph nodes
was the only independent prognostic factor for shorter OS in the multivariate analysis. Further multivariate
analysis of the patients with node-positive disease showed that the Malay ethnic group, ER negativity and more
than five positive lymph nodes were independent prognostic factors for shorter RFS. On the other hand, ER
negativity and more than five positive lymph nodes were independent negative prognostic factors for OS in this
subgroup of patients.
CONCLUSION: The evaluation of various prognostic factors would provide useful information on disease
progression in local patients, especially for the planning of adjuvant therapies and follow-up protocols. Differences
in the pattern of breast cancer among the different ethnic groups in Malaysia warrant further studies. [Asian J Surg
2003;26(3):169–75]
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tackled accordingly.
Prognostic factors are useful to clinicians and patients
because they help to prognosticate individual cases and serve
as a guide in the planning of adjuvant therapies. The presence
of certain prognostic factors also predicts the patients’ response
to specific hormonal or novel immunotherapies, e.g. oestrogen
receptor (ER) response to tamoxifen and c-erbB-2 response to
trastuzumab. Because there is still no universal follow-up
protocol for breast cancer patients,4 clinicopathological
variables of prognostic significance could serve as useful guides
for planning the most cost-effective and optimum follow-up
strategy.
While axillary nodal status has been the traditional mainstay
predictor for recurrence and survival in primary breast
cancers,5 many clinicopathological and molecular factors have
been extensively studied in the search for the “best” prognostic
marker. Apart from the problem of different patient selection
criteria and methodologies in various studies, the matter is
further complicated by the fact that clinicopathological
variables change in their prognostic importance during follow-
up,6 as some factors have their greatest prognostic value
immediately after primary treatment, whereas others may
retain their prognostic significance after the first recurrence
and even during long-term follow-up. Data on prognostic
indicators for breast cancer in Malaysia are lacking.
This study aimed to determine the impact of various
clinicopathological variables of prognostic significance on
short-term outcomes in a cohort of breast cancer patients,
treated in the Breast Clinic of the University of Malaya Medical
Centre, who have no evidence of distant metastases at
presentation, i.e. stage I to III disease. Cases with stage IV
disease at presentation often have very poor outlook and, thus,
were excluded from the current analysis.
Methods
This was a retrospective study of all breast cancer cases treated
in the Breast Clinic of the University of Malaya Medical Centre
from January 1999 to June 2001 (over a 30-month period).
Clinical and follow-up data were obtained from case records,
and pathological information from the individual patients’
histopathological reports. These data made up the database of
patients of the Breast Clinic. Cases of carcinoma in situ,
malignant phylloides tumours and sarcomas were excluded.
For the purpose of this study, cases with distant metastases at
presentation (which generally have dismal prognosis) were
excluded from the analysis. The clinicopathological variables
included in the analysis were ethnic group, age at presentation,
tumour size, nodal status, number of positive lymph nodes,
tumour grade, ER status and presence of lymphovascular
invasion (LVI).
The SPSS (Statistical Package for the Social Sciences)
software, version 10.0 (SPSS Inc., Chicago, IL, USA), was used
for statistical analyses. The information was entered into an
SPSS database. Unavailable information was treated as missing
data and the respective cells in the database were left blank.
Univariate analyses were performed using the Chi-squared
test to test for the association of categorical variables. The
short-term outcomes analysed were recurrence-free survival
(RFS) and overall survival (OS). RFS was defined as the period
from the date of diagnosis to the date of diagnosis of recurrence,
for either locoregional or systemic recurrences. OS was defined
as the period from the date of diagnosis to the date of death
from any cause. In this study, all deaths were attributed to
breast cancer. All the time periods were calculated in months.
Univariate analyses for prognostic significance of various
variables were done using the Kaplan-Meier procedure.
Statistical differences between the survival curves were analysed
using the log-rank test. Cox regression analysis was used for
multivariate analysis.
Results
A total of 460 breast cancer cases were seen over the study
period, of which 385 (83.7%) had no evidence of distant
metastases at presentation (stages I–III). The characteristics of
the 385 patients who presented with stage I to III disease are
listed in Table 1. The primary and adjuvant treatments received
by the patients are summarized in Table 2.
The mean follow-up for this cohort of patients was 18.7
months (median, 19 months; standard deviation, SD, 8.8
months). During the follow-up period, 33 patients had
recurrences and 15 patients died from breast cancer.
In the univariate analysis for RFS, the following factors
were associated with shorter RFS, either locoregional or
systemic: Malay ethnicity (p = 0.012), tumours larger than
2 cm in diameter (p = 0.001) lymph node-positive tumours
(p < 0.001), more than five positive lymph nodes (p < 0.001), ER
negativity (p < 0.001) and presence of LVI (p = 0.007). Age at
diagnosis and tumour grade had no significant relationship
with RFS. Further multivariate analyses considering age and
various significant variables showed that ER negativity was the
only significant independent prognostic factor for short-term
RFS (Table 3; Figure 1).
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In the OS study, univariate analyses revealed that tumours
larger than 2 cm in diameter (p = 0.003), lymph node-positive
tumours (p = 0.002), more than five positive lymph nodes
(p = 0.004), ER negativity (p = 0.005) and high-grade (grade 3)
tumours (p = 0.020) were associated with shorter OS. Ethnicity,
age and LVI did not appear to have a significant impact on
short-term OS. In the multivariate analyses, more than five
positive lymph nodes was the only significant independent
prognostic factor for OS (Table 4; Figure 2).
When the cases were analysed based on lymph node status,
it was obvious that patients with node-negative disease had a
much lower incidence of recurrence or death from breast
cancer. During follow-up, only four cases of recurrence and
one death were noted in the node-negative group of patients,
Table 1. Patient characteristics
Total number of patients 385
Age at diagnosis, yr (mean ± SD) 50.3 ± 11.4
Ethnic group, n (%)
Malay 90 (23.4)
Chinese 235 (61.0)
Indian 53 (13.8)
Others 7 (1.8)
Stage at diagnosis, n (%)
I 92 (23.9)
II 217 (56.4)
III 76 (19.7)
Tumour diameter, cm (mean ± SD) 3.7 ± 2.7
T stage, n (%)
T1 113 (29.4)
T2 193 (50.1)
T3 39 (10.1)
T4 40 (10.4)
Lymph node status, n (%)
Positive 198 (51.4)
Negative 187 (48.6)
Tumour grade, n (%)
1 31 (10.9)
2 150 (52.8)
3 103 (36.3)
Unavailable (not included ) 101
Oestrogen receptor status, n (%)
Positive 202 (59.9)
Negative 135 (40.1)
Unavailable 48
Lymphovascular invasion, n (%)
Yes 71 (33.2)
No 143 (66.8)
Unavailable 171
Table 2. Primary and adjuvant treatments
Primary treatment of node-positive patients, n
Mastectomy 120
Breast conservation surgery 27
Chemotherapy 30
Tamoxifen 7
Paclitaxel 3
Data unavailable 11
Node-positive patients receiving adjuvant therapy, %
Chemotherapy 95.2
Radiotherapy 96.4
Tamoxifen 60.7
Primary treatment of node-negative patients, n
Mastectomy 108
Breast conservation surgery 63
Chemotherapy 5
Tamoxifen 6
Data unavailable 5
Node-negative patients receiving adjuvant therapy, %
Chemotherapy 65.9
Radiotherapy 53.8
Tamoxifen 63.6
Figure 1. Recurrence-free survival (RFS) based on oestrogen receptor
(ER) status for stage I–III breast cancers.
Table 3. Results of Cox regression analysis: recurrence-free survival
for stage I–III breast cancers
Factor Wald Chi-squared p
Oestrogen receptor negative 4.083 0.043
Ethnic group (Malay) 0.193 0.660
Tumour size > 2 cm 0.002 0.964
Lymph node-positive 1.588 0.208
Lymphovascular invasion 0.138 0.711
Age < 40 yr 1.019 0.313
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whereas 29 cases of recurrence and 14 deaths occurred in the
node-positive group.
In a separate analysis of survival in node-positive patients,
Malay patients (p = 0.014), tumour size larger than 2 cm
(p = 0.026), more than five positive lymph nodes (p < 0.001) and
ER negativity (p = 0.005) were associated with shorter RFS in
univariate analyses. In multivariate analyses, Malay ethnicity,
more than five positive lymph nodes and ER negativity were
the independent prognostic factors for short-term RFS in
node-positive patients (Table 5; Figure 3).
Univariate analyses for OS in node-positive patients showed
that younger age (< 40 years) at diagnosis (p = 0.046), more
than five positive lymph nodes (p = 0.004) and ER negativity
(p = 0.028) were associated with shorter OS. In multivariate
analyses, more than five positive lymph nodes and ER negativity
were the independent prognostic factors for short-term OS
(Table 6).
The above analyses reveal that there are differences in
survival among different ethnic groups, specifically in the
event of recurrence. Thus, further study of the differences in
characteristics of breast cancers in the various ethnic groups
are warranted. When all the breast cancer cases are taken into
Table 4. Results of Cox regression analysis: overall survival for
stage I–III breast cancers
Factor Wald Chi-squared p
Positive lymph nodes > 5 4.113 0.043
Tumour grade 3 0.813 0.367
Tumour size > 2 cm 0.001 0.973
Oestrogen receptor negative 2.890 0.089
Age < 40 yr 0.432 0.511
Figure 2. Overall survival (OS) based on the number of positive
lymph nodes (LN) for stage I–III breast cancers.
Figure 3. Recurrence-free survival (RFS) based on ethnic group for
node-positive, stage I-III breast cancers.
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Table 5. Results of Cox regression analysis: recurrence-free survival
for node-positive, stage I–III breast cancers
Factor Wald Chi-squared p
Positive lymph nodes > 5 11.260 0.001
Oestrogen receptor negative 7.609 0.006
Malay ethnicity 5.330 0.021
Tumour size > 2 cm 2.910 0.088
Age < 40 yr 0.012 0.912
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consideration, i.e. stages I to IV, Malay patients appeared to
present at a younger age (< 40 years) (Chi-squared; p = 0.002),
with a higher disease stage (stage III or IV) (p = 0.001), have
larger tumours (> 5 cm) (p = 0.003) and a higher incidence of
node-positive disease (p = 0.001). However, when only patients
with stage I to III disease are analysed, there were no significant
differences in disease stage at presentation among the various
ethnic groups (p = 0.096). In this group of patients (with stage
I–III disease), Malay patients seemed to present at a younger
age (< 40 years) (p = 0.001) and have a higher incidence of node-
positive disease (p = 0.019).
Discussion
In this study, a number of key clinicopathological variables
were examined in a cohort of local patients with breast cancer
in a Malaysian population, from a single institution, with
a team specializing in breast cancer care. As the analyses
concentrated on short-term outcomes, the information
derived is helpful for the planning of management strate-
gies for patients during the first 2 years of follow-up after
diagnosis.
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Based on the results, lymph node status played a critical
role in determining the outlook for breast cancer patients.
This issue has been extensively evaluated and nodal status has
become the “standard” prognostic factor.5,7,8 The number of
lymph nodes involved with metastases appears to be a very
important variable because it stands out as a prominent
independent prognostic factor for RFS and OS in the cohort
of patients in this study, especially for node-positive patients.
This observation is consistent with other studies on this aspect
of breast cancer management.9–12 There is evidence that nodal
metastasis is not only a marker of diagnosis at a later point in
the natural history of breast cancer (chronological age of the
individual cancer),13 but is also a marker of an aggressive
breast cancer phenotype.8 This finding supports the role of
axillary lymph node dissection in the management of breast
cancer. Besides the role for locoregional disease control for
node-positive breast cancer, the number of dissected lymph
nodes is also of prognostic value in node-negative cases.14,15 It
is clear that, in order to provide optimum care, clinicians
should work closely with pathologists to give the most
informative nodal assessment.
In the current study, ER status was an independent
prognostic factor for RFS regardless of nodal status, as it was
for OS in node-positive patients as well. This gives ER status a
prominent role as a prognostic indicator in the first 1 to 2 years
after breast cancer diagnosis. The prognostic role of ER was
first noted in 1977.16 It is now a well-established fact that the
absence of ERs is related to a poorer outcome.17,18 More
specifically, there is evidence that the ER content in breast
cancer seems to be an indicator of growth rate rather than of
metastatic potential, and accordingly, a predictor of the pattern
of recurrence and length of disease-free survival rather than of
long-term survival.19 This is consistent with the results of our
study. On the other hand, progesterone receptor (PR) status
appears to be more closely associated with OS.20 Further
studies on PR expression in local breast cancer patients might
provide extra prognostic information. In the long run, it
would be interesting to see if ER status maintains its prognostic
value since it appears to lose its prognostic significance in
long-term follow-up.19,21
Controversy abounds regarding the role of age in the
prognosis of breast cancer. There is evidence that younger
patients have worse outcomes compared to patients who
present with breast cancer at an older age, because younger
patients are believed to have more aggressive disease.22–24
However, the evidence on this matter is not conclusive.25,26 In
our study, age younger than 40 years was a significant adverse
prognostic factor for OS in node-positive patients in univariate
analysis. In other survival analyses, age did not appear to have
a significant impact on outcomes. However, there was a trend
for younger patients to have poorer survival in terms of
recurrence and death from disease, even though it did not
reach statistical significance. This is an aspect that should be
further studied and kept in mind when managing local breast
cancer patients.
Tumour size, a “traditional” core prognostic factor,7,27 was
only a significant prognostic factor in the univariate analyses
for RFS and OS, but not in the multivariate analyses for RFS
and OS. This is not a total surprise. Primary breast cancer can
often be controlled with surgery or radiotherapy. With proper
surgical technique, complete excision of a primary tumour
with good margins can be consistently achieved. Further-
more, some studies have shown that patients with extremely
large tumours tend to have better outcomes than those
with tumours of intermediate size.28 It was postulated that
tumours that have grown to a large size without killing the
patient or causing nodal spread might have a lower metastatic
potential.28
One striking finding in our study was that there were
significant differences in RFS among the different ethnic
groups in this cohort of patients. Compared to the other
ethnic groups, Malay patients appeared to have shorter RFS in
the univariate analysis. In the node-positive subgroup of
patients, Malay ethnicity was an independent adverse factor
for RFS in the multivariate RFS analysis. Is this association
real? A total of 90 Malay patients with stage I to III disease were
included in the study (23.4% of the total patients), of which 41
were available for RFS analysis in the node-positive subgroup.
Although the number of patients is modest, it is adequate to
show any statistically significant difference compared to the
other ethnic groups. Is this tendency for Malay patients to
develop recurrence due to unique tumour pathology or is it
secondary to sociocultural differences? There is no clear answer
to this question. A review of tumour characteristics (taking all
cases into consideration, stages I–IV) showed that Malay
Table 6. Results of Cox regression analysis: overall survival for
node-positive, stage I–III breast cancers
Factor Wald Chi-squared p
Positive lymph nodes > 5 4.761 0.029
Oestrogen receptor negative 5.084 0.024
Tumour size > 2 cm 1.854 0.173
Age < 40 yr 1.091 0.296
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patients tended to present at a younger age, with higher
disease stage, larger tumour size, and tended to have node-
positive breast cancer. When only stage I to III cancers are
considered, Malay patients appeared to present at a younger
age and with node-positive disease. Taken together, it appears
that a larger proportion of Malay patients had adverse
prognostic variables. A review of the literature showed that
differences in recurrence and survival exist between different
ethnic groups, whether in the same country or between different
countries. For instance, Japanese patients with breast cancer
show a 5% to 15% 10-year survival advantage over Caucasian
patients,29 and African-Americans have lower survival rates
compared to other American patients, even after adjusting
for disease stage.30,31 Besides tumour pathology, many other
factors can affect disease progression in breast cancer. Are
Malay patients presenting late to the hospital? Do they prefer
traditional therapy (herbal medicine and massage) to hospital-
based treatment? These questions need to be answered if we
aim to provide the best care to all breast cancer patients in
Malaysia.
The pathological variables of tumour grade and LVI did
not appear to have a significant impact on survival in this
cohort of patients. Higher grade tumours were associated with
shorter OS in univariate analyses, and LVI was associated with
shorter RFS. Inter-observer variation is a major problem in
interpretation of tumour grade and LVI,32 and has made
histopathological grading of low prognostic value in individual
patients.33 Unless a standardized method of interpretation is
agreed on by specialists in this field, inconsistency in
interpretation will prove to be an obstacle to the use of tumour
grade and LVI in the prognosis of breast cancer.34
Summary
The number of positive lymph nodes and ER status are the
most important prognostic variables for OS and RFS,
respectively. Both variables are also independent prognostic
factors for OS and RFS in the subgroup of node-positive
patients. Knowledge of these two variables is of great clinical
importance in prognosticating and in the planning of adjuvant
therapies and follow-up strategies for breast cancer patients.
We emphasize that the information for the current study is
concentrated on short-term outcomes, i.e. in the first 1 to
2 years after the diagnosis of breast cancer, when the level
of stress for both patients and clinicians is intense in looking
for the best treatment plan. We hope that our data are of use
in the planning of local treatment and follow-up protocols.
Suggestions could be made to extend the current study to
yield further information regarding longer-term survival. This
would be helpful in long-term follow-up because the value of
various prognostic factors changes dynamically with time.
Other markers, e.g. c-erbB-2, p53, Ki-67 and others, should
also be explored to study their prognostic values in local
patients. As the database expands and the follow-up period
lengthens, meaningful analysis of survival in the node-negative
subgroup could be done. This work is important because
significant prognostic factors could help in the decision-
making process for adjuvant therapies in this group of patients,
who generally have a better outlook. Furthermore, the study of
ethnic differences in breast cancers in the multiracial society of
Malaysia would give a different perspective on the pathology
of breast cancers.
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